Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bc8ad885ecf662fe30245929f5e534476> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bc8ad885ecf662fe30245929f5e534476 NCIT_P378 "NCI" @default.
- Bc8ad885ecf662fe30245929f5e534476 type Axiom @default.
- Bc8ad885ecf662fe30245929f5e534476 annotatedProperty IAO_0000115 @default.
- Bc8ad885ecf662fe30245929f5e534476 annotatedSource NCIT_C116377 @default.
- Bc8ad885ecf662fe30245929f5e534476 annotatedTarget "A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR." @default.